Pembrolizumab vs Ipilimumab in Advanced Melanoma: Long-Term Follow-up
Posted: 07/25/2023 | By: Sarah Campen, PharmD

A 7-year follow-up of the KEYNOTE-006 trial, published by Robert et al in the Journal of Clinical Oncology, tracked outcomes among patients with advanced melanoma who had received treatment with either pembrolizumab or ipilimumab.

Question 1 of 5

After 7 years of follow-up, what was the rate of overall survival in patients receiving pembrolizumab vs ipilimumab?

Choose 1